PET/CT Limitations and Pitfalls in Urogenital Cancers

Anil Vasireddi, Nghi C. Nguyen

Research output: Contribution to journalReview articlepeer-review

7 Scopus citations


Hybrid FDG PET/CT plays a vital role in oncologic imaging and has been widely adopted for the staging and restaging of a variety of malignancies. Its diagnostic value in urogenital malignancies is less well-known, not at least because of the variable FDG avidity of these tumor entities, the sites of these tumors, and technical challenges associated with sequential imaging of CT and PET. PET/CT interpretation thus can be especially challenging and is associated with many pitfalls, which can lead to both false-positive and false-negative diagnoses as well as incorrect assessment of metabolic change following therapy. Currently, FDG PET/CT is not the standard of care for the initial diagnosis or staging of early-stage or low-risk urogenital cancers; however, it can help evaluate distant metastatic disease, response to therapy, and disease recurrence in high-risk patients. Knowledge of imaging features of tumor metabolic avidity and pitfalls is essential for accurate interpretation.

Original languageEnglish (US)
Pages (from-to)611-620
Number of pages10
JournalSeminars in Nuclear Medicine
Issue number6
StatePublished - Nov 2021
Externally publishedYes

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging


Dive into the research topics of 'PET/CT Limitations and Pitfalls in Urogenital Cancers'. Together they form a unique fingerprint.

Cite this